Journal scan

TAS-102 improves overall survival in metastatic colorectal cancer

Study to determine the effects of a novel drug on survival rate 

In this pooled, retrospective cohort study, available data on neutropenia counts were analysed from 149 patients with refractory metastatic colorectal cancer who were treated with a novel combination oral nucleoside antitumour agent called TAS-102 (trifluridine and tipiracil hydrochloride).

The patient records were reviewed from four institutions: three North American and one comparative validation population from Japan.

The aim of the study was to determine the effect of the drug on overall survival, focusing on the predictive value of developing chemotherapy-induced neutropenia (CIN), as defined by the Common Terminology Criteria for Adverse Events, at one month.

Overall, 46% of patients developed CIN (greater than or equal to grade 2) at one month after initiation of the treatment, and this was associated with a benefit to overall prognosis. The patients who developed this degree of CIN were found to have


Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Cancer Nursing Practice
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?